Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069831 · ClinicalTrials.gov registry record · Phase 1
JAK Inhibition in Food Allergy
A Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT05069831 is a Phase 1 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 71 participants.
The verdict
NCT05069831, a Phase 1 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
This study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. Abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in many patients with multiple atopic conditions.
Interventions
- DRUG Abrocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05069831
The ClinicalTrials.gov registry entry for NCT05069831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abrocitinib is the first listed.
NCT05069831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05069831 about?
NCT05069831 is a clinical study titled "JAK Inhibition in Food Allergy". This study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. Abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in...
What is the current status of trial NCT05069831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2022-05-16. Estimated completion is 2025-06-13.
What interventions are being tested in trial NCT05069831?
The interventions under investigation include: Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT05069831?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.